Dermatology Treatment Devices Market Size Set for Explosive Growth, With Projections Indicating $ 21.86 billion by 2031 | The Insight Partners
17 déc. 2024 06h51 HE
|
The Insight Partners
US & Canada, Dec. 17, 2024 (GLOBE NEWSWIRE) -- According to a new comprehensive report from The Insight Partners, the Global Dermatology Treatment Devices Market is expected to reach US$ 21.86...
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
13 déc. 2024 14h55 HE
|
Palvella Therapeutics Inc.
Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for...
Inflation Reduction Act Likely to Shape Specialty Prescribing Decisions in 2025, According to Spherix Global Insights
10 déc. 2024 09h59 HE
|
Spherix Global Insights
EXTON, PA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various national priorities,...
ViaDerma Announces Significant 2024 Achievements and International Expansion
10 déc. 2024 08h00 HE
|
ViaDerma, Inc.
LOS ANGELES, Dec. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, proudly announces the completion of a...
AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer
09 déc. 2024 07h03 HE
|
AiViva Biopharma
AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma...
Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory Board
25 nov. 2024 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company developing safe and highly effective topical treatments...
Trent Renta Promoted to Chief Operating Officer at Olansky Dermatology & Aesthetics in Atlanta, Georgia
18 nov. 2024 16h44 HE
|
Olansky Dermatology & Aesthetics
Trent Renta promoted to Chief Operating Officer
at Olansky Dermatology & Aesthetics in Atlanta, Georgia.
MJH Life Sciences® acquires Revolutionizing Atopic Dermatitis (RAD) Annual Meeting, expands leadership in dermatology education
18 nov. 2024 11h00 HE
|
MJH Shared Services, LLC
CRANBURY, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MJH Life Sciences®, a premier provider of health care events, media, and education, today announced the acquisition of the Revolutionizing Atopic...
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
15 nov. 2024 00h59 HE
|
Regeneron Pharmaceuticals, Inc.
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by...
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
14 nov. 2024 16h10 HE
|
Fortress Biotech, Inc.
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally...